Compare Abeona Therapeutics Inc (ABEO) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Capital One Financial Corp. — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Capital One Financial Corp. trades at $192.87 (market cap $124.98B). The key difference: Capital One Financial Corp. is far larger — about 334.8× Abeona Therapeutics Inc's market cap, and Capital One Financial Corp. pays a 1.58% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | COF | |
|---|---|---|
Market Cap | $373.32M | $124.98B |
Sector | Health | Financials |
52-Week High | $7.23 | $257.94 |
52-Week Low | $4.17 | $176.10 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Capital One (COF) trades at $202.89, down 1.09% with a bullish technical outlook despite recent earnings misses. The stock shows strong analyst support with 62.5% buy ratings and a $252 consensus target, representing 24% upside. Recent financials reveal revenue growth to $53.43B in 2025 but declining net margins to 4.59%, while cash flow improved significantly to $18.42B. The company faces regulatory scrutiny and credit risk concerns but benefits from Discover integration and expanding software offerings.
COF presents a compelling risk-reward profile with substantial upside to analyst targets, though investors must weigh strong institutional support against margin pressure and economic sensitivity. The Discover acquisition provides long-term scale advantages, but near-term performance depends on credit quality stability and successful integration execution amid potential recessionary headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
